| 1 | 1 | | I |
|---|
| 2 | 2 | | 119THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION H. R. 1432 |
|---|
| 5 | 5 | | To prohibit any Federal law from making the manufacturer of a COVID– |
|---|
| 6 | 6 | | 19 vaccine immune from suit or liability, or limiting the liability of |
|---|
| 7 | 7 | | such a manufacturer, with respect to claims for loss caused by, arising |
|---|
| 8 | 8 | | out of, relating to, or resulting from the administration to or the use |
|---|
| 9 | 9 | | by an individual of a COVID–19 vaccine, and for other purposes. |
|---|
| 10 | 10 | | IN THE HOUSE OF REPRESENTATIVES |
|---|
| 11 | 11 | | FEBRUARY18, 2025 |
|---|
| 12 | 12 | | Mr. R |
|---|
| 13 | 13 | | OY(for himself, Mr. MASSIE, Mr. BRECHEEN, Mr. CLOUD, Mr. HIGGINS |
|---|
| 14 | 14 | | of Louisiana, Mr. C |
|---|
| 15 | 15 | | RANE, Mr. GOSAR, and Mr. PERRY) introduced the |
|---|
| 16 | 16 | | following bill; which was referred to the Committee on the Judiciary |
|---|
| 17 | 17 | | A BILL |
|---|
| 18 | 18 | | To prohibit any Federal law from making the manufacturer |
|---|
| 19 | 19 | | of a COVID–19 vaccine immune from suit or liability, |
|---|
| 20 | 20 | | or limiting the liability of such a manufacturer, with |
|---|
| 21 | 21 | | respect to claims for loss caused by, arising out of, |
|---|
| 22 | 22 | | relating to, or resulting from the administration to or |
|---|
| 23 | 23 | | the use by an individual of a COVID–19 vaccine, and |
|---|
| 24 | 24 | | for other purposes. |
|---|
| 25 | 25 | | Be it enacted by the Senate and House of Representa-1 |
|---|
| 26 | 26 | | tives of the United States of America in Congress assembled, 2 |
|---|
| 27 | 27 | | VerDate Sep 11 2014 01:13 Mar 12, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1432.IH H1432 |
|---|
| 28 | 28 | | ssavage on LAPJG3WLY3PROD with BILLS 2 |
|---|
| 29 | 29 | | •HR 1432 IH |
|---|
| 30 | 30 | | SECTION 1. SHORT TITLE. 1 |
|---|
| 31 | 31 | | This Act may be cited as the ‘‘Let Injured Americans 2 |
|---|
| 32 | 32 | | Be Legally Empowered Act’’ or the ‘‘LIABLE Act’’. 3 |
|---|
| 33 | 33 | | SEC. 2. NO FEDERAL IMMUNITY FROM, OR LIMITATION ON, 4 |
|---|
| 34 | 34 | | LIABILITY FOR MANUFACTURERS FOR LOSS 5 |
|---|
| 35 | 35 | | CAUSED BY A COVID–19 VACCINE. 6 |
|---|
| 36 | 36 | | (a) I |
|---|
| 37 | 37 | | NGENERAL.—No Federal law, including sec-7 |
|---|
| 38 | 38 | | tions 319F–3, 2111, and 2122 of the Public Health Serv-8 |
|---|
| 39 | 39 | | ice Act (42 U.S.C. 247d–6d, 300aa–11, 300aa–22), may 9 |
|---|
| 40 | 40 | | make the manufacturer of a COVID–19 vaccine immune 10 |
|---|
| 41 | 41 | | from suit or liability, or limit the liability of such a manu-11 |
|---|
| 42 | 42 | | facturer, with respect to claims for loss caused by, arising 12 |
|---|
| 43 | 43 | | out of, relating to, or resulting from the administration 13 |
|---|
| 44 | 44 | | to or the use by an individual of a COVID–19 vaccine. 14 |
|---|
| 45 | 45 | | (b) R |
|---|
| 46 | 46 | | ULE OFCONSTRUCTION.—Nothing in this Act 15 |
|---|
| 47 | 47 | | shall be construed to prohibit an individual from seeking 16 |
|---|
| 48 | 48 | | compensation through the Countermeasures Injury Com-17 |
|---|
| 49 | 49 | | pensation Program under section 319F–4 of the Public 18 |
|---|
| 50 | 50 | | Health Service Act (42 U.S.C. 247d–6e) or the National 19 |
|---|
| 51 | 51 | | Vaccine Injury Compensation Program under subtitle 2 20 |
|---|
| 52 | 52 | | of title XXI of such Act (42 U.S.C. 300aa–10 et seq.). 21 |
|---|
| 53 | 53 | | (c) R |
|---|
| 54 | 54 | | ELATION TOOTHERPROGRAMS.—An individual 22 |
|---|
| 55 | 55 | | shall not be precluded from bringing a civil action for 23 |
|---|
| 56 | 56 | | claims described in subsection (a) on the basis of such in-24 |
|---|
| 57 | 57 | | dividual having sought or received compensation through 25 |
|---|
| 58 | 58 | | the Countermeasures Injury Compensation Program 26 |
|---|
| 59 | 59 | | VerDate Sep 11 2014 01:13 Mar 12, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H1432.IH H1432 |
|---|
| 60 | 60 | | ssavage on LAPJG3WLY3PROD with BILLS 3 |
|---|
| 61 | 61 | | •HR 1432 IH |
|---|
| 62 | 62 | | under section 319F–4 of the Public Health Service Act 1 |
|---|
| 63 | 63 | | (42 U.S.C. 247d–6e) or the National Vaccine Injury Com-2 |
|---|
| 64 | 64 | | pensation Program under subtitle 2 of title XXI of such 3 |
|---|
| 65 | 65 | | Act (42 U.S.C. 300aa–10 et seq.). 4 |
|---|
| 66 | 66 | | (d) D |
|---|
| 67 | 67 | | EFINITION.—The term ‘‘COVID–19 vaccine’’ 5 |
|---|
| 68 | 68 | | means a vaccine licensed or otherwise authorized by the 6 |
|---|
| 69 | 69 | | Food and Drug Administration to prevent, mitigate, or 7 |
|---|
| 70 | 70 | | limit— 8 |
|---|
| 71 | 71 | | (1) the harm from COVID–19; or 9 |
|---|
| 72 | 72 | | (2) the transmission of SARS–CoV–2 or a virus 10 |
|---|
| 73 | 73 | | mutating therefrom. 11 |
|---|
| 74 | 74 | | (e) R |
|---|
| 75 | 75 | | ETROACTIVEAPPLICABILITY.—This Act applies 12 |
|---|
| 76 | 76 | | without regard to whether the adminstration or use of a 13 |
|---|
| 77 | 77 | | COVID–19 vaccine occurs before, on, or after the date of 14 |
|---|
| 78 | 78 | | enactment of this Act. 15 |
|---|
| 79 | 79 | | Æ |
|---|
| 80 | 80 | | VerDate Sep 11 2014 01:13 Mar 12, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6301 E:\BILLS\H1432.IH H1432 |
|---|
| 81 | 81 | | ssavage on LAPJG3WLY3PROD with BILLS |
|---|